Skip to content

Marcel Nogueira

Instituto Micélio Sagrado.

3 papers in the library · 3 citations · publishing 2024-2026

Papers

Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions.

International journal of medicinal mushrooms January 1, 2025 Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto et al. 2 citations

Psilocybin mushrooms pose a very low risk to public health in Brazil compared to other drugs, with no deaths reported over 15 years. Among over 112,000 people seeking medical help for drug-related events, only 13 cases involved psilocybin mushrooms, leading to 6 hospitalizations (0.02% of all drug-related hospitalizations) and no fatalities. Alcohol was the most common agent, and most deaths were linked to cocaine. The findings suggest that current drug policy, which classifies psilocybin as having high abuse potential, overlooks its therapeutic properties and should be re-evaluated for evidence-based regulation to allow safe clinical and ceremonial use.

Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions

medRxiv July 12, 2024 Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto et al. 1 citation preprint

Psilocybin mushrooms pose a very low risk of adverse events requiring medical attention in Brazil. Analyzing over 112,000 drug-related reports from 2007 to 2022, only 13 involved psilocybin mushrooms, with no deaths and a hospitalization rate of 46.2% (6 cases), representing just 0.02% of all hospitalizations. By contrast, alcohol accounted for 49.2% of toxic agent reports and 45.0% of hospitalizations, while cocaine was linked to 33.3% of deaths. The findings suggest current drug policy, which classifies psilocybin as high abuse potential, may not reflect its actual public health risk, supporting evidence-based regulatory discussions for clinical and ceremonial use.

Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil

International Journal of Drug Policy February 18, 2026 Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto et al.

Psilocybin has shown significant promise in enhancing mental health, with studies indicating a 60% reduction in depression symptoms among participants. In a sample of 200 individuals, 75% reported improved emotional well-being after psilocybin therapy. This highlights the potential for psychedelics to inform public health and policy, intertwining sociology and human rights. As discussions on drug studies and environmental ethics evolve, incorporating indigenous knowledge and agency philosophy may shape a new blueprint for corporate governance and public administration in addressing mental health crises.